↓ Skip to main content

Immune-related response assessment during PD-1 inhibitor therapy in advanced non-small-cell lung cancer patients

Overview of attention for article published in Journal for Immunotherapy of Cancer, December 2016
Altmetric Badge

About this Attention Score

  • Good Attention Score compared to outputs of the same age (70th percentile)
  • Average Attention Score compared to outputs of the same age and source

Mentioned by

twitter
9 tweeters
reddit
1 Redditor

Citations

dimensions_citation
80 Dimensions

Readers on

mendeley
70 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Immune-related response assessment during PD-1 inhibitor therapy in advanced non-small-cell lung cancer patients
Published in
Journal for Immunotherapy of Cancer, December 2016
DOI 10.1186/s40425-016-0193-2
Pubmed ID
Authors

Mizuki Nishino, Nikhil H. Ramaiya, Emily S. Chambers, Anika E. Adeni, Hiroto Hatabu, Pasi A. Jänne, F. Stephen Hodi, Mark M. Awad

Abstract

Tumor response characteristics using immune-related RECIST1.1 (irRECIST1.1) in advanced non-small-cell lung cancer (NSCLC) patients treated with nivolumab monotherapy in the clinical setting have not been previously described with a direct comparison with the assessments according to the conventional RECIST1.1. Fifty-six advanced NSCLC patients treated with nivolumab monotherapy after its Food and Drug Administration (FDA) approval were retrospectively studied. Tumor burden was quantified on serial CT scans during therapy using irRECIST1.1, which uses unidimensional measurements and includes new lesion measurements in total tumor burden. Response assessments by irRECIST1.1 were compared with assessments by RECIST1.1. Responses of individual lesions in different organs were also compared. Tumor burden change at best overall response ranged from -66.8 to +278.1% (median: +3.9%). Response rate was 14% (8/56; 8 partial responses, 0 complete responses) by irRECIST1.1 and by RECIST1.1. Time-to-progression (TTP) by irRECIST1.1 was longer than TTP by RECIST1.1 (median TTP: not reached vs. 1.9 months, respectively). No patients experienced pseudoprogression during the study. Among 128 target lesions, the lesion-based size change at best response differed significantly across different organs, with adrenal lesions and lymph nodes having greater size decrease, followed by lung, while liver and other miscellaneous lesions had lesser degree of size decrease (p = 0.002). Immune-related response evaluations using irRECIST1.1 in advanced NSCLC patients treated with nivolumab resulted in the identical response rate and longer TTP compared to RECIST1.1. No pseudoprogression cases were observed during the study. Adrenal lesions and lymph nodes were more responsive and liver lesions were less responsive to nivolumab.

Twitter Demographics

The data shown below were collected from the profiles of 9 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 70 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
United States 1 1%
Unknown 69 99%

Demographic breakdown

Readers by professional status Count As %
Researcher 14 20%
Other 12 17%
Student > Master 9 13%
Student > Postgraduate 8 11%
Student > Bachelor 4 6%
Other 13 19%
Unknown 10 14%
Readers by discipline Count As %
Medicine and Dentistry 28 40%
Agricultural and Biological Sciences 6 9%
Pharmacology, Toxicology and Pharmaceutical Science 5 7%
Biochemistry, Genetics and Molecular Biology 5 7%
Engineering 2 3%
Other 2 3%
Unknown 22 31%

Attention Score in Context

This research output has an Altmetric Attention Score of 5. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 04 January 2017.
All research outputs
#5,274,191
of 19,196,842 outputs
Outputs from Journal for Immunotherapy of Cancer
#1,007
of 2,110 outputs
Outputs of similar age
#119,602
of 403,436 outputs
Outputs of similar age from Journal for Immunotherapy of Cancer
#39
of 78 outputs
Altmetric has tracked 19,196,842 research outputs across all sources so far. This one has received more attention than most of these and is in the 72nd percentile.
So far Altmetric has tracked 2,110 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 14.0. This one has gotten more attention than average, scoring higher than 51% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 403,436 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 70% of its contemporaries.
We're also able to compare this research output to 78 others from the same source and published within six weeks on either side of this one. This one is in the 48th percentile – i.e., 48% of its contemporaries scored the same or lower than it.